A detailed history of Pdt Partners, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 145,519 shares of APLS stock, worth $4.82 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
145,519
Previous 92,856 56.71%
Holding current value
$4.82 Million
Previous $3.56 Million 17.83%
% of portfolio
0.41%
Previous 0.36%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $1.52 Million - $2.17 Million
52,663 Added 56.71%
145,519 $4.2 Million
Q2 2024

Aug 15, 2024

BUY
$38.07 - $59.71 $1.38 Million - $2.17 Million
36,335 Added 64.29%
92,856 $3.56 Million
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $253,132 - $331,187
4,570 Added 8.8%
56,521 $3.32 Million
Q4 2023

Feb 14, 2024

SELL
$37.14 - $64.82 $504,175 - $879,931
-13,575 Reduced 20.72%
51,951 $3.11 Million
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $955,838 - $3.61 Million
40,416 Added 160.96%
65,526 $2.49 Million
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $635,370 - $773,166
8,286 Added 49.25%
25,110 $2.29 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $783,830 - $1.13 Million
16,824 New
16,824 $1.11 Million
Q3 2022

Nov 14, 2022

SELL
$44.76 - $69.66 $1.05 Million - $1.63 Million
-23,390 Reduced 38.41%
37,504 $2.56 Million
Q2 2022

Aug 15, 2022

BUY
$35.07 - $59.21 $2.14 Million - $3.61 Million
60,894 New
60,894 $2.75 Million
Q1 2020

May 15, 2020

SELL
$17.91 - $44.33 $1.43 Million - $3.55 Million
-80,017 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$22.1 - $30.8 $716,371 - $998,382
32,415 Added 68.1%
80,017 $2.45 Million
Q3 2019

Nov 14, 2019

BUY
$24.09 - $32.18 $257,329 - $343,746
10,682 Added 28.93%
47,602 $1.15 Million
Q2 2019

Aug 14, 2019

BUY
$18.0 - $25.34 $153,360 - $215,896
8,520 Added 30.0%
36,920 $936,000
Q1 2019

May 15, 2019

BUY
$12.81 - $19.82 $363,804 - $562,888
28,400 New
28,400 $554,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.